Pembrolizumab for advanced adrenocortical cancer that keeps growing
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent and be age 18 or older
- You have a confirmed diagnosis of adrenocortical carcinoma (a specific adrenal gland cancer)
- Your overall health score must be below a certain level (ECOG less than 2)
- Your scans must show measurable cancer, and it must have progressed within the last 6 months after at least one chemotherapy treatment
- Your blood counts and organ lab tests must be within required limits (kidneys, liver, and clotting)
- If you can become pregnant or father a child, you must use two reliable birth-control methods and have a negative pregnancy test (for those who can get pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Hear when a new Adrenocortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.